CLEC2D Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant CLEC2D.
- 产品详情
- 实验流程
- 背景知识
Application
| WB, IHC, E |
|---|---|
| Primary Accession | Q9UHP7 |
| Other Accession | BC019883 |
| Reactivity | Human |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG1 Kappa |
| Clone Names | 4C7 |
| Calculated MW | 21849 Da |
| Gene ID | 29121 |
|---|---|
| Other Names | C-type lectin domain family 2 member D, Lectin-like NK cell receptor, Lectin-like transcript 1, LLT-1, Osteoclast inhibitory lectin, CLEC2D, CLAX, LLT1, OCIL |
| Target/Specificity | CLEC2D (AAH19883, 1 a.a. ~ 154 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IHC~~1:100~500 E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | CLEC2D Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene encodes a member of the natural killer cell receptor C-type lectin family. The encoded protein inhibits osteoclast formation and contains a transmembrane domain near the N-terminus as well as the C-type lectin-like extracellular domain. Several alternatively spliced transcript variants have been identified, but the full-length nature of every transcript has not been defined.
REFERENCES
1.Induction of LLT1 cell surface expression by pathogens and IFN-{gamma} contributes to modulate immune responses.Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, Lazzari A, Neisig A, Hakansson K, Dong T, Wagtmann N, Galsgaard ED, Spee P, Braud VM.J Biol Chem. 2011 Sep 19.2.Characterization of Alternatively Spliced Transcript Variants of CLEC2D Gene.Germain C, Bihl F, Zahn S, Poupon G, Dumaurier MJ, Rampanarivo HH, Padkjar SB, Spee P, Braud VM.J Biol Chem. 2010 Nov 12;285(46):36207-15. Epub 2010 Sep 14.3.Functional Consequences of Interactions between Human NKR-P1A and Its Ligand LLT1 Expressed on Activated Dendritic Cells and B Cells.Rosen DB, Cao W, Avery DT, Tangye SG, Liu YJ, Houchins JP, Lanier LL.J Immunol. 2008 May 15;180(10):6508-17.4.Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1.Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M.Cancer Res. 2007 Apr 15;67(8):3540-4.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。